TIMOTHY KIMUYU: Open Payments
NPI 1790203016 · MANSFIELD, TX. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$4,934 in 153 payments from 17 companies in 2025. Trend: 2023 $1,570 · 2024 $3,299 · 2025 $4,934
Food & beverage: $4,808Education: $126
| Company | Payments | Amount |
|---|---|---|
| Neurocrine BioSciences, Inc. | 27 | $1,124 |
| Janssen Pharmaceuticals, Inc | 23 | $719 |
| Teva Pharmaceuticals USA, Inc. | 24 | $674 |
| Alkermes, Inc. | 20 | $627 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 18 | $496 |
| Otsuka America Pharmaceutical, Inc. | 8 | $379 |
| E.R. Squibb & Sons, L.L.C. | 10 | $205 |
| ABBVIE INC. | 5 | $187 |
| Vanda Pharmaceuticals Inc. | 8 | $171 |
| Janssen Scientific Affairs, LLC | 1 | $138 |
Products named: INGREZZA, INVEGA SUSTENNA, CAPLYTA, ARISTADA, UZEDY, REXULTI, AUSTEDO XR, COBENFY.
Industry payments across TX — which companies pay providers there.
